Last reviewed · How we verify

NCT05204667: MioPain

Different Dosage Regimens of Methocarbamol/Paracetamol in Acute Non-specific Low Back Pain. MioPain Study

Terminated Phase 4 Last updated 31 January 2025
What this trial tests

Phase 4 trial testing 380 mg/300 mg comprimidos metocarbamol/paracetamol - 4 times daily in Low Back Pain in 172 participants. Terminated before completion.

Timeline
7 October 2021
Primary endpoint
3 November 2023
28 February 2024

Quick facts

Lead sponsorAziende Chimiche Riunite Angelini Francesco S.p.A
PhasePhase 4
StatusTerminated
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment172
Start date7 October 2021
Primary completion3 November 2023
Estimated completion28 February 2024
Sites3 locations across Italy

Drugs / interventions tested

Conditions studied

Sponsor

Aziende Chimiche Riunite Angelini Francesco S.p.A — full company profile →

Who can join

Adults 18 to 64, any sex, with Low Back Pain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the study is to evaluate the efficacy and safety of different dosage regimens of the combination methocarbamol/paracetamol in the treatment of patients with acute non-specific Low Back Pain.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Low Back Pain

Currently open trials in the same condition.

Other Aziende Chimiche Riunite Angelini Francesco S.p.A trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05204667.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing